Navigation Links
FDA Approves New HIV Treatment
Date:5/20/2011

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Edurant belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitor (NNRTI). The drug works by blocking HIV viral replication. Edurant is to be used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV (viral load) in the blood. Edurant is a pill taken once a day with food.

"Patients may respond differently to various HIV drugs or experience varied side effects. FDA's approval of Edurant provides an additional treatment option for patients who are starting HIV therapy," said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.

The safety and effectiveness of Edurant is based on 48-week data from two Phase 3 clinical trials with 1,368 adult subjects with HIV infection, and from a 96-week (with extension to 192 weeks) trial. Patients had not received prior HIV therapy and were selected to receive treatment with Edurant or efavirenz (another FDA-approved NNRTI for the treatment of HIV infection). Both drugs were given in combination with other antiretroviral drugs.

Edurant was as effective as efavirenz in lowering viral load. In the Edurant and efavirenz groups, 83 percent and 80 percent of subjects, respectively, had undetectable amounts of HIV in their blood after 48 weeks of treatment. Patients receiving Edurant who had a higher viral load at the start of therapy were more likely not to respond to the drug than were patients with a lower viral load at the start of thera
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... MOUNTAIN VIEW, Calif., Jan. 4, 2011 PneumRx, Inc. ... bringing innovation and improvements to the treatment of lung ... in working capital commitments.  The oversubscribed round was led ... both leading venture capital firms from Europe, and also ...
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
Cached Medicine Technology:PneumRx, Inc. Raises $33 Million in Capital 2PneumRx, Inc. Raises $33 Million in Capital 3Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:7/11/2014)... 11, 2014 As part of ... Liebhard LLP has been closely monitoring the ongoing ... (FDA) Obstetrics and Gynecology Devices Panel, which ... the cancer risks associated with the use of ... to a report published by Dow Jones Business ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... Supplements, Specialty Nutrients, Animal Feed), Applications (Regular, Therapeutic, ... - Global Trends & Forecasts to 2019 ” ... an analysis and forecasting of the market value ... identifies the driving and restraining factors for the ...
(Date:7/11/2014)... disposable medical suppliers call for the biggest share of ... past two decades, the world market for disposable medical ... year), primarily owing to the importance of these products ... market for disposable medical supplies in the world, accounting ... held by Europe with a 29% market share. The ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... five years to 2014 on the heels of fresh ... prompted farmers to dedicate a larger share of their ... More specifically, the regulations required the mixing of 5.0% ... biofuel production in the United States created a key ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
... draws attention to urgency in preventing stroke and supporting 6 million stroke ... ... This year nearly 795,000 people will have a stroke, leaving a path ... to National Stroke Association , which is observing National Stroke Awareness ...
... Everywhere, Inc. filed a federal complaint today seeking an injunction against the ... ... Everywhere, Inc . filed a federal complaint today seeking an injunction against ... import of Electronic Cigarettes. The company believes the use of inhaled nicotine ...
... provide telephone based triage and health advice to EosHealth service ... As EosHealth subscribers manage their health through interactive resources via ... health triggers and proactively reach out to perform triage and ... ...
... in Alzheimer,s disease, people become less efficient at separating ... found. , Knowing this, clinicians may be able ... to remember high-value information better, according to a report ... by the American Psychological Association. , Remembering what,s ...
... PARK, Calif., May 4 Acclarent, Inc., the pioneer ... the treatment of chronic sinusitis, announced today that the ... 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders ... This patent and Acclarent,s earlier 7,462,175 patent are ...
... Steps to Prevent Spreading FluNORRISTOWN, Pa., May 3 ... first laboratory-confirmed case of 2009 A/H1N1 in a 31-year-old ... confirmed case, it is even more important for the ... can help prevent the spread of the flu," said ...
Cached Medicine News:Health News:Four of Five Families Will Be Touched by Stroke in 2009 2Health News:Press Release: Electronic Cigarette VS FDA 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 2Health News:SironaHealth to Provide 24 x 7 Nurse Line and Clinical Outreach to EosHealth as part of their Mobile Health & Wellness Programs 3Health News:Memory grows less efficient very early in Alzheimer's disease 2Health News:Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 3
For the qualitative detection of group A Streptococcal antigen from throat swabs...
For the qualitative detection of human Chorionic Gonadotrophin (hCG) in urine or serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
Medicine Products: